Video Experimental Relacionado
Updated: Jul 8, 2026
13:09
Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet
Published on: July 31, 2021
Estrategias farmacológicas en el tratamiento de la obesidad
1Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808, USA. BrayGA@pbrc.edu
Nature
|April 15, 2000
Resumen
El tratamiento de la obesidad requiere medicamentos efectivos que reduzcan la ingesta de energía o aumenten el gasto. El manejo de la obesidad a largo plazo requiere el uso continuo de terapias como la sibutramina u orlistat, a menudo en combinación.
Área de la Ciencia:
- Farmacología Farmacología.
- Endocrinología Endocrinología.
- Salud Pública La salud pública.
Sus antecedentes:
- La obesidad es una enfermedad prevalente, crónica y costosa.
- El tratamiento farmacológico es necesario cuando la prevención falla.
- La obesidad a menudo es estigmatizada, lo que afecta la adherencia del paciente.
Objetivo del estudio:
- Revisar los tratamientos medicinales actuales para la obesidad.
- Para discutir el desarrollo estratégico de nuevos medicamentos para la obesidad.
- Para resaltar la naturaleza crónica de la obesidad y las necesidades de tratamiento.
Principales métodos:
- Revisión de los medicamentos para la obesidad actualmente aprobados.
- Análisis de los mecanismos de acción de los medicamentos para el control de peso.
- Discusión de estrategias terapéuticas para el control de la obesidad a largo plazo.
Principales resultados:
- La sibutramina y el orlistat están aprobados para el tratamiento a largo plazo de la obesidad.
- La sibutramina actúa inhibiendo la ingesta de alimentos.
- Orlistat funciona bloqueando la digestión de las grasas de la dieta.
Conclusiones:
- El tratamiento de la obesidad requiere la adherencia a largo plazo y puede beneficiarse de la terapia de combinación.
- Los medicamentos efectivos para la obesidad deben reducir la ingesta de energía, aumentar el gasto de energía o ambos.
- El desarrollo estratégico de fármacos debe considerar la obesidad como una enfermedad crónica y progresiva.
Videos de Conceptos Relacionados
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...